within Pharmacolibrary.Drugs.ATC.C;

model C05BX51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 2.9166666666666666e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C05BX51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Calcium dobesilate is a vasoprotective drug mainly used for the management of chronic venous insufficiency and diabetic retinopathy. Its combinations may be used with other agents for the treatment of vascular disorders, particularly those involving capillary fragility. Its use is approved in several countries, though not in the United States.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies specifically for calcium dobesilate, combinations (ATC C05BX51) were found in the literature. The reported values here are estimated from data on calcium dobesilate monotherapy administered orally in healthy adult subjects.</p><h4>References</h4><ol><li><p>Angulo, J, et al., &amp; Sáenz de Tejada, I (2003). Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. <i>British journal of pharmacology</i> 139(4) 854–862. DOI:<a href=&quot;https://doi.org/10.1038/sj.bjp.0705293&quot;>10.1038/sj.bjp.0705293</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12813009/&quot;>https://pubmed.ncbi.nlm.nih.gov/12813009</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C05BX51;
